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Background: The benign character formerly attributed to Plasmodium vivax infection has been dismantled by the
increasing number of reports of severe disease associated with infection with this parasite, prompting the need for
more thorough and comprehensive characterization of the spectrum of resulting clinical complications. Endemic areas
exhibit wide variations regarding severe disease frequency. This study, conducted simultaneously in Brazil and India,
constitutes, to our knowledge, the first multisite study focused on clinical characterization of P. vivax severe disease.
Methods: Patients admitted with P. vivax mono-infection at reference centers in Manaus (Amazon - Brazil) and Bikaner
(Rajasthan - India), where P. vivax predominates, were submitted to standard thorough clinical and laboratory
evaluations in order to characterize clinical manifestations and identify concurrent co-morbidities.
Results: In total, 778 patients (88.0% above 12 years old) were hospitalized at clinical discretion with PCR-confirmed
P. vivax mono-infection (316 in Manaus and 462 in Bikaner), of which 197 (25.3%) presented at least one severity
criterion as defined by the World Health Organization (2010). Hyperlactatemia, respiratory distress, hypoglycemia, and
disseminated intravascular coagulation were more frequent in Manaus. Noteworthy, pregnancy status was associated
as a risk factor for severe disease (OR = 2.03; 95% CI = 1.2-3.4; P = 0.007). The overall case fatality rate was 0.3/1,000 cases
in Manaus and 6.1/1,000 cases in Bikaner, with all deaths occurring among patients fulfilling at least one severity
criterion. Within this subgroup, case fatality rates increased respectively to 7.5% in Manaus and 4.4% in Bikaner.
Conclusion: P. vivax-associated severity is not negligible, and although lethality observed for complicated cases was
similar, the overall fatality rate was about 20-fold higher in India compared to Brazil, highlighting the variability observed
in different settings. Our observations highlight that pregnant women and patients with co-morbidities need special
attention when infected by this parasite due to higher risk of complications.
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Malaria is a major public health problem in most trop-
ical regions, and despite impressive reductions in the
number of cases and deaths in the last decades, malaria
resulted in an estimated 207 million episodes and
627,000 deaths in 2012 [1]. Although the attention of* Correspondence: marcuslacerda.br@gmail.com
1Programa de Pós-graduação em Medicina Tropical, Universidade do Estado
do Amazonas, Av. Pedro Teixeira, 25, Manaus, AM 69040-000, Brazil
2Gerência de Malaria, Fundação de Medicina Tropical Dr Heitor Vieira
Dourado, Av. Pedro Teixeira, 25, Manaus, AM 69040-000, Brazil
Full list of author information is available at the end of the article
© 2015 Siqueira et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.the scientific community has focused in past decades on
the burden and consequences of P. falciparum infections
[2,3], in recent years there has been a renewed interest in
P. vivax-associated morbidity, as a result of the increasing
report of its potential hazards to health [4-7].
P. vivax is the most geographically widespread parasite
causing malaria in humans, with over 2.5 billion individ-
uals exposed to the risk of infection; it is the predominant
species in Latin America and some areas of the Asian and
Pacific regions [1,8]. In a context of renewed and intensi-
fied commitment of the international community towardsl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Epidemiological profile of the two studied sites: P. vivax 2010 annual parasite index in Brazil (A) and India (B) (reproduced
from the Malaria Atlas Project [8]); malaria transmission scenarios in the rainforest, Manaus, Brazil (C) and in the desert, Bikaner, India
(D); reference tertiary care center façades in Manaus (E) and Bikaner (F).
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emerged regarding this species, possibly because of the
major challenges posed for its control, ensuing from its
poorly understood ability to present clinical relapses
[5,10], but also due to its capacity to cause a more compli-
cated disease [11-13]. P. vivax benign clinical course has
now been completely reconsidered, as the evidence of
life-threatening disease has been reported from diverse
endemic areas, such as Latin America [7,14,15], India
[16,17], and Southeast Asia and the Pacific regions [18,19].
In spite of the World Health Organization (WHO) recog-
nition as early as 2006 of the potential of P. vivax to cause
severe disease [20], there are still several gaps in know-
ledge to be filled [5,11,21,22].
The diverse range and rate of occurrence of clinical
complications associated to P. vivax infection widely dif-
fer according to reports from different endemic regions,
suggesting that many unaccounted factors, including
those related to the parasite, the host, or the context in
which the infection is produced may interact in causing
the clinical presentation [12]. Indeed not all endemic areas
have been reporting severity attributed to infection with
this parasite, such as the Thailand-Myanmar border, where
severity was reported only very recently [23]. In the
absence of adequate experimental models, or the paucity
of postmortem samples to further elucidate the patho-
physiology of this infection [5,13,24], systematic multi-
site clinical studies become a unique opportunity to better
understand this geographic variability and characterize the
severe vivax malaria syndrome. Indeed, comprehensive
reviews of the literature demonstrate that severe vivax mal-
aria occurrence is an old, and not infrequent, phenomenon
that was not being properly recognized [12,25,26].
We have used a common protocol in order to pro-
spectively follow vivax malaria patients admitted to two
distinct reference centers located in Brazil and India,
aiming to comprehensively characterize and compare
the clinical complications of P. vivax infection.
Methods
Study sites
The enrollment of cases was performed at two different
reference tertiary hospitals located in Brazil and India.
Fundação de Medicina Tropical Dr Heitor Vieira Dourado
(FMT-HVD) is located in the city of Manaus, in
the Brazilian Western Amazon, with 150 beds for
hospitalization. This hospital is the reference tropical
medicine and infectious disease center for the area, and
receives patients from all over the Amazonas state, re-
ferred or not to this service. Admission is free of charge,
and admission criteria for malaria patients are any
clinical complications suggestive of severe malaria, or
complications impacting proper antimalarial treatment,
such as severe vomiting. Six other hospitals in town arethe reference for pediatric diseases. Anopheles darlingi
is the major malaria vector in the region, with transmis-
sion occurring continuously throughout the year with
peaks in the beginning of the dry and the wet season. In
recent years there has been a decrease in the number of
reported episodes paralleled to an increase in the
proportion of cases attributed to P. vivax, which is now
responsible for more than 90% of cases of malaria in the
region [27]. Sardar Patel Medical College (SPMC) hos-
pital is located in Bikaner in the Rajasthan state of India,
where, as a result of environmental and climatic rea-
sons, malaria transmission has a well-defined seasonal
pattern with practically no cases being reported during
the dry season, and P. vivax is responsible for 50% of
the cases [28]. An. stephensi, An. culifascies, and An.
annularis are the major malaria vectors in the region
(Figure 1). The hospital includes around 500 beds for
hospitalization in general, and a specific malaria ward,
which remains closed except for the duration of the
malaria season. The hospital receives referrals from the
entire Rajasthan state, although other hospitals (includ-
ing private ones) are also available for patients in the
area. Admission is free with the exception of certain
subsidized procedures, and during the malaria season
most of the patients are routinely admitted to this ward,
often because they are being referred. Neither of the
two hospitals is a specifically pediatric referral center,
although pediatric patients may be admitted in both.
Study design and patient selection
This was a hospital-based study of patients admitted
with vivax malaria at the two study centers, regional ref-
erences mostly for the adult population. Enrollment in
Manaus occurred in two distinct periods (between April
2009 and March 2010, and between January 2011 and
December 2011), while in Bikaner patients were recruited
between August 2009 and October 2010. All initial
microscopy-confirmed P. vivax infections (or patients with
negative thick blood smears (TBSs) but with history of
previous recent diagnosis in use of antimalarials) requiring
admission, at clinician’s discretion (for example, for the
presence of jaundice, thrombocytopenia, bleeding, vomit-
ing, diarrhea, abdominal pain, non-lithiasic cholecystitis,
spleen rupture, or overall compromised clinical status),
regardless of age, were eligible for enrollment provided
patients or their legal representatives signed an informed
consent. All enrolled patients were hospitalized in separate
wards designed for clinical research and were followed
and evaluated daily until discharge, when the final out-
come of each case was registered after consensual discus-
sion performed by the clinical team involved in the study.
The same protocol for clinical and laboratory investiga-
tions was applied at both sites, including standard operat-
ing procedures (SOPs) and questionnaires. The study
Table 1 Demographic and epidemiological characteristics of enrolled patients at both sites
Severe Non-severe P
N = 197 N = 518
Female sex 133 (55.5%) 225 (43.5%) 0.003
Age < 12 years old 10 (5.1%) 23 (5.0%) 0.422
Duration of fever (days): Mean (SD) 5.4 (3.8) 5.7 (7.1) 0.453*
First malarial infection 27 (12.7%) 88 (16.5%) 0.187
Antimalarials in the preceding 30 days 41 (18.6%) 78 (14.2%) 0.030
Geometric mean P. vivax density on admission (parasites/mm3; 95% CI)¶ 2,267 (1,872-2,745) 1,902 (1,667-2,169) <0.001
Pregnancy (among females of reproductive age) 37/114 (32.5%) 97/227 (18.5%) 0.004
Any co-morbidity 31 (15.9%) 92 (17.8%) 0.527
Heart rate (beats/min): Mean (SD) 87.1 (12.8) 85.0 (11.8) 0.032*
Respiratory rate (breaths/min): Mean (SD) 18.8 (4.0) 19.4 (4.9) 0.126*
Temperature (°C): Mean (SD) 37.9 (1.1) 37.5 (1.1) <0.001*
Hepatomegaly 47 (21.6%) 141 (25.8%) 0.217
Splenomegaly 68 (31.2%) 131 (24.0%) 0.041
Hemoglobin (g/dL): Mean (SD) 7.7 (3.1) 10.9 (2.6) <0.001*
White blood cell count (× 1,000 cells/mm3): Mean (SD) 8.6 (10.4) 6.5 (3.8) <0.001*
Platelets (× 1,000 cells/mm3): Mean (SD) 74.1 (88.9) 72.5 (90.9) 0.824*
Creatinine (mg/dL): Mean (SD) 1.4 (1.6) 0.9 (0.4) <0.001*
Urea (mg/dL) : Mean (SD) 51.2 (49.7) 38.9 (20.3) <0.001*
Total bilirubin (mg/dL): Mean (SD) 2.9 (5.9) 2.2 (3.5) 0.0498*
ALT (U/L): Mean (SD) 50.5 (85.6) 42.2 (81.3) 0.222*
Lactate (mmol/L): Mean (SD) 5.0 (13.4) 2.0 (2.5) 0.010*
P-value obtained by chi-square test or Student t test with the latter identified (*); ¶restricted to patients without prior exposure to antimalarials (P-value derived
from Poisson regression).
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investigators from both sites and supervised by study moni-
tors from ISGlobal (authors QB and CG) to minimize
potential discrepancies in their application.
Clinical evaluation and management
At enrollment all patients underwent an initial compre-
hensive clinical assessment based on a clinical history and
physical examination. Data were prospectively collected
using a standardized questionnaire, which included the
description of the duration and intensity of the clinical
symptoms, a thorough clinical examination, and comple-
mentary tests (complete blood cell count and biochemical
analyses). The history of previous malaria infections and
antimalarial use was obtained through medical history and
health surveillance and health unit records revision. Blood
samples were collected for PCR confirmation of P. vivax
mono-infection and for a detailed evaluation of coexisting
acute and chronic morbidities, when suspected by the cli-
nicians, while women of reproductive age were additionally
tested routinely for their pregnancy status. When available
at each site, and according to individual clinical presenta-
tion, imaging exams were performed, such as abdominal ortrans-vaginal ultrasound, computerized tomography, and
fundoscopy. Treatment was provided according to WHO
recommendations and national guidelines, with the use of
chloroquine (25 mg/kg over 3 days) in non-complicated
patients, or parenteral artemether or artesunate in patients
with suspicion of severe malaria or severe vomiting,
followed by primaquine (3.5 mg/kg over 7 days in Brazil,
and over 14 days in India) [29,30]. In India, patients with
severe criteria were also systematically prescribed wide
spectrum antibiotics upon admission. Clinical assessments
and TBS were performed on a daily basis. Additional and
follow-up laboratory tests were performed at the physi-
cian’s discretion.
Diagnosis of malaria
For the diagnosis and quantification of parasitemia,
the TBS was prepared as recommended by the Walker
technique [31]. In addition to the reading performed for
patients’ diagnosis, each blood slide was analyzed inde-
pendently by two microscopists. A slide was recorded as
negative if no parasite was detected in the 200-field
reading. If parasites were detected on the slide, quantifi-
cation was performed by counting the number of
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or 500 parasites were counted (whichever occurred
first). In case of discordance (species-specific, or in the
density quantification whenever discrepancy was higher
than 10%), a third reading was performed by a different
microscopist. The parasite density was calculated by the
arithmetic mean of two concordant readings and the
white blood cell count obtained from the total blood
count analysis as previously described [32]. In addition,
species-specific real-time PCR for Plasmodium was per-
formed to confirm P. vivax mono-infection status and
exclude P. falciparum co-infection. P. malariae was not
tested considering previous data from both sites con-
firming the absence of circulation of this species in the
study areas. The extraction of total DNA from whole
blood was performed using the QIAamp DNA 144
Blood Mini KitW (Qiagen, USA), according to the manu-
facturer’s protocol, and amplification was done in an
Applied Biosystems 7500 Fast SystemW using primers
and TaqMan fluorescence labeled probes [33].
Case definitions and classification
Patients were classified in relation to their clinical
symptomatology and laboratory results. The presence of
the WHO-defined severe malaria criteria and syndromes
was systematically assessed at admittance and during the
whole length of hospitalization at both sites, with cases
being classified accordingly to the criteria described in
Table 1 [30]. The results for the worst tests were re-
corded in the Case Report Form (CRF) and the last
results were used for case closure purposes. The sys-
tematic assessment at admission consisted of full blood
count, biochemistry analyses (creatinine, urea, biliru-
bin, aspartate aminotransferase, alanine aminotransfer-
ase, gamma-glutamyltransferase, albumin, and venous
lactate), urine analysis, pregnancy tests for women
between 12 and 50 years of age, and chest X-rays. We
also classified patients according to the number of
severe criteria fulfilled as a proxy of higher severity, for
which more specific and easier applicable criteria [7]
were used: severe anemia (hemoglobin <7 g/dL in
adults and <5 g/dL in children); respiratory distress/
acute lung injury; circulatory shock (systolic blood
pressure < 90 mmHg refractory to fluid); acute renal
failure; and cerebral malaria. A cut-off was decided to
categorize cases as more severe if they presented three
or more severe criteria.
The performance of additional investigations for co-
morbidities was triggered either for specific manifesta-
tions and/or at the physician’s discretion. These criteria
included: i) severe anemia: hemoglobinopathies investi-
gation and glucose-6-phosphate dehydrogenase (G6PD)
assessments, and abdominal ultrasound; ii) respiratory
distress: chest X-rays, blood gas, chest computerizedtomography (CT) scan, and blood cultures; iii) ALT. 200
U/L: serology against hepatitis A, hepatitis E (only in
India), and dengue; iv) creatinine > 3 mg/dL: renal ultra-
sound, 24-h proteinuria measurement and creatinine
clearance; v) cerebral malaria: CT scan and lumbar
puncture (if not contraindicated); and vi) severe abdom-
inal pain: abdominal ultrasound. HIV testing (serology)
was conducted for all admitted patients. Additionally,
co-infection with dengue fever (by serology and PCR),
and leptospirosis (serology) were systematically investi-
gated in all admitted patients in Manaus. Blood cultures
were performed in Bikaner, although samples were col-
lected after patients had been started on antibiotics, a prac-
tice which is routine among patients with severity criteria.
In Manaus, two blood culture samples were drawn for all
admitted patients with severe criteria (10 mL of blood).
Chronic co-morbidities were determined based on pa-
tients’ provided information and assessment of medical
records. For these analyses, patients admitted due to
primaquine-induced hemolysis (only observed in Manaus)
were excluded, and the details concerning its presentation
and outcomes will be presented in a separate publication
(in preparation).
Statistical analysis
All the data were double entered in forms designed in the
Open ClinicaW online platform, with the discordances and
inconsistencies corrected according to a pre-established
protocol. Only hospitalized patients with PCR-confirmed
P. vivax mono-infection were included for the analyses.
The demographic and clinical characteristics of patients
were described in terms of proportions and compared
using the chi-square or Fisher test as appropriate.
Unadjusted simple logistic regression analyses were also
performed considering different outcomes, especially the
fulfillment of WHO severe criteria for P. falaciparum [20]
and death. Further description and analyses were per-
formed for each of the main severe complications ob-
served in order to provide a broader picture of the clinical
spectrum of this infection. Unadjusted linear regression
was undertaken to explore the association between num-
ber of severe criteria and risk factors. Multiple analyses
were not performed, because the sample size did not offer
sufficient power for that purpose. The diagnostic perform-
ance of laboratorial parameters for identifying severity or
multiplicity of severity criteria was assessed by means
of receiver operating characteristic (ROC) curves. The
analyses were performed using SPSSW version 16.0 for
Windows (SPSSW Inc. Chicago, IL, USA) and Stata version
13.1 (StataCorpW, College Station, TX, USA).
Ethical considerations
The study was approved by the Ethics Review Board
(ERB) of Hospital Clínic, Barcelona, Spain (4510/2008),
Figure 2 Number of diagnosed, hospitalized, severe, and deceased p
(A) and Bikaner (B).
Table 2 Description of chronic and acute co-morbidities
diagnosed in P. vivax-infected patients admitted to two
reference centers in Brazil and India
n
Chronic co-morbidities* 84
Arterial hypertension 34
Diabetes 28
Chronic hepatitis C infection1 14
HIV/AIDS2 8
Chronic hepatitis B infection3 8
Chronic renal failure 2
Acute co-morbidities and investigations 87
Blood culture
Dengue fever4 68
Pneumonia 9
Enteric fever 3
Lepstopirosis5 2
Hepatitis A infection6 2
Varicella-zoster virus meningoencephalitis 1
Sickle cell disease crisis 1
Diphteria 1
1Defined by positive anti-HCV serology; 2defined by serology; 3defined by positive
HBsAg; 4defined by positive PCR and/or NS1 test; 5defined by positive IgM;
6defined by positive IgM anti-HAV.
*Uncertain denominators as investigations were made at attending
physician’s discretion.
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Vieira Dourado, Manaus, Brazil (1943/2008), the National
Brazilian Committee of Ethics (CONEP) (343/2009), and
the ERB of Sardar Patel Medical College & Associated
Groups of Hospitals, Bikaner, India (24/12/2008).Results
Study subjects
During the study period, 316 and 462 patients were
admitted with vivax malaria in Manaus and Bikaner
respectively (Figure 2 and Table 1) with three and seven
associated fatalities per site. Among the patients with
fatal outcome, there was a predominance of women
(eight patients), four of them pregnant, with patients from
Manaus presenting higher age and number of co-
morbidities compared to Bikaner. The characteristics of the
10 patients with fatal outcome are presented in Additional
file 1: Table S1. Only in Manaus was P. falciparum/P. vivax
co-infection seen in one patient with severe criteria. Among
patients without WHO criteria, no deaths were observed.
On admission, 24 patients had a negative TBS, all of them
having initiated antimalarials in other health units, of which
PCR was positive for P. vivax in 14 of them. There were 47
patients admitted in Manaus due to primaquine-associated
hemolysis and associated complications, all of them with
G6PD deficiency, with no patient being diagnosed with this
condition in Bikaner.atients with P. vivax malaria, during the study period in Manaus
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in Manaus more patients with co-morbidities were
admitted, however with similar proportion of deaths
(Table 2). Antibiotics were administered to 24 patients
in Manaus, for treatment of pneumonia in 16 patients,
cellulitis in 4 patients, amebiasis in 2, and enteritis in 2.
Although blood and urine cultures were obtained from
all these patients prior to therapy, only in one patient
was a microorganism identified (Staphylococcus aureus
associated with cellulitis). In Bikaner, antibiotics were
administered to 230 patients (with 62.7% of those with
at least one severe criterion receiving them). Additional
investigations were performed, as aforementioned, at
physicians’ discretion or triggered by specific manifesta-
tions, limiting the estimation of its occurrence within
the study population. The main chronic and acute
co-morbidities diagnosed in these patients are described
in Table 2. Dengue fever co-infection, due to its high
occurrence and public health importance in Manaus,
has been described in another publication [34].
Clinical manifestations and severity
Patients presented a varied array of clinical complications
associated with P. vivax mono-infection, including atypicalTable 3 Epidemiological and clinical characteristics of P. vivax
India, with the diagnosis of severe malaria according to WHO
Demographic and epidemiological characteristics
Female sex
Age <12 years old
First malarial infection
Pregnancy (among females of reproductive age)
Clinical characteristics
Severe anemia (Hb < 5 g/dl if age < 12 and Hb < 7 if age≥ 12)
Acute renal failure (Creatinine > 3 mg/dL and/or urinary output < 0.5 ml/kg/h
Hyperlactatemia (lactate > 5 mmol/L)
Respiratory distress (PaO2/FiO2≤ 300 mmHg and/or bilateral opacities on X-r
Hypoglycemia (blood glucose < 40 mg/dL)
Shock (SBP > 90 mmHg refractory to fluid resuscitation)
DIC (prolonged aPTT, platelet < 50x109/L and elevated FDP)
Cerebral malaria (GCS≤ 9 in adults or BCS≤ 2 in children and/or repeated co
Two or more complications
Three or more complications
Presence of any other acute co-morbidity
Presence of any chronic co-morbidity
Death
P-value obtained by chi-square test or Fisher test with the latter identified (*); Hb, h
oxygen; SBP, systolic blood pressure; DIC, disseminated intravascular coagulation; a
product; GCS, Glasgow Coma Scale; BCS, Blantyre Coma Scale.complications seen only on imaging exams. Anemia was
the more frequent complication at both sites, followed by
acute renal failure. Respiratory distress, hyperlactatemia,
hypoglycemia, and disseminated intravascular coagulation,
although rare, were mostly seen in Manaus (Table 3).
There was a higher proportion of patients presenting with
three or more complications in Bikaner compared to
Manaus (16.2% versus 10.7%, respectively; P = 0.063), with
no further discrepancies observed between sites.
For the outcome of presenting at least one of the
WHO severe malaria criteria, there was association with
female gender, first malarial infection, and pregnancy.
For multiple severity criteria, the only variable showing
evidence of association was the presence of chronic co-
morbidity, with borderline evidence for an association
with both pregnancy status and female gender. There
was evidence of association of female gender as a risk
factor for death among P. vivax admitted patients, and
although the proportions of individuals with chronic
co-morbidities and non-pregnant women were higher
among the patients who died, the differences were not
meaningful and the lack of power needs to be taken into
consideration (Table 4). Similar findings resulted when
the same analysis was performed per site (data notpatients admitted to tertiary care centers in Brazil and
criteria
Manaus (Brazil) Bikaner (India) P
16/40 (40.0%) 98/157 (62.4%) 0.010
7/40 (17.5%) 3/157 (1.9%) <0.001
25/40 (62.5%) 149/150 (99.3%) <0.001
11/16 (68.8%) 67/98 (68.4%) 0.976
19/40 (47.5%) 83/157 (53.2%) 0.519
for 6 hours) 9/40 (22.5%) 18/157 (11.5%) 0.073*
5/40 (15.2%) 4/157 (2.6%) 0.343*
ay) 7/40 (17.5%) 5/157 (3.2%) 0.002*
4/40 (10.0%) 1/157 (0.7%) 0.001*
3/40 (7.6%) 7/157 (4.6%) 0.463*
2/40 (5.0%) 0/157 (0%) 0.005*
nvulsions) 1/40 (2.5%) 5/157 (3.2%) 0.817*
20/40 (50.0%) 75/157 (47.8%) 0.801
5/40 (12.5%) 16/157 (10.2%) 0.673*
6/40 (15.0%) 6/157 (0.6%) <0.001*
14/40 (35.0%) 4/157 (2.5%) <0.001*
3/40 (7.5%) 7/157 (4.4%) 0.434*
emoglobin; PaO2, partial pressure of arterial oxygen; FiO2, fraction of inspired
PTT, activated partial thromboplastin time; FDP, fibrinogen degradation
Table 4 Univariate analysis of risk factors associated to WHO severe disease, three or more severity criteria, and death, in P. vivax patients admitted to two
tertiary care centers in Brazil and India
Severe
n/N (%)
Non-severe
n/N (%)
OR (95% CI) P Presence of three
or more severe
criteria n/N (%)
Absence of three
or more severe
criteria n/N (%)
OR (95% CI) P Dead
n/N (%)
Survived
n/N (%)
OR (95% CI) P
Female gender 114/197 (57.9) 230/518 (44.4) 1,7 (1.2-2.4) 0.001 14/21 (66.7) 330/694 (47.6) 1.7 (1.1-2.7) 0.022 8/10 (80.0) 336/705 (47.7) 2.6 (0.8-8.4) 0.119
Age < 12 years old 10/197 (5.1) 21/518 (4.0) 1.3 (0.6-2.9) 0.476 2/21 (9.5) 25/694 (3.6) 1.3 (0.4-4.5) 0.647 0/10 (0) 27/705 (3.8) - 0.440
First malarial infection 174/190 (91.6) 431/501 (86.0) 1.8 (1.1-3.1) 0.044 3/20 (15.0) 83/671 (12.4) 1.0 (0.5-2.2) 0.725 7/10 (70.0) 598/681 (87.8%) 0.3 (0.1-1.3) 0.090
Pregnancy¶ 36/114 (31.6) 40/230 (17.4) 2.3 (1.3-3.8) 0.003 8/14 (57.1) 65/330 (19.7) 3.2 (1.7-6.1) <0.001 4/8 (50.0) 78/336 (23.3) 2.6 (0.7-10.1) 0.157
Peripheral parasitemia
>5,110 parasites/mm3*
18/98 (18.4) 43/149 (28.9) 0.6 (0.3-1.0) 0.063 10/46 (21.7) 51/201 (25.4) 0.8 (0.4-1.8) 0.607 4/9 (44.4) 57/238 (24.0) 2.5 (0.7-9.8) 0.175
Duration of fever prior
to admission >7 days
32/197 (16.5) 156/517 (30.3) 0.5 (0.3-0.8) 0.008 2/21 (12.0%) 157/694 (22.7) 0.5 (0.2-1.2) 0.098 1/10 (10.0) 184/705 (26.2) 0.4 (0.1-2.9) 0.329
Presence of any acute
co-morbidity
7/197 (3.6) 31/518 (6.0) 0.7 (0.3-1.6) 0.439 4/21 (19.0) 38/694 (5.5) 1.3 (0.4-3.9) 0.648 2/10 (20.0) 38/705 (5.4) 5.3 (0.7-24.0) 0.084
Presence of any chronic
co-morbidity
18/197 (9.1) 60/518 (11.6) 0.9 (0.5-1.4) 0.349 6/21 (28.6) 72/674 (10.4) 1.1 (0.5-2.0) 0.008 3/10 (30.0) 75/705 (10.6) 4.0 (1.2-13.3) 0.051*
¶Analysis restricted to women of reproductive age (12-50 years-old); *restricted to patients not in use of antimalarials at the initial assessment (5,110 parasites/mm3 was the lower limit of the highest quartile).
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Siqueira et al. BMC Medicine  (2015) 13:57 Page 9 of 14shown). Further characterization of specific manifesta-
tions is shown below. An additional linear regression
analysis on the association with the number of severe
criteria in each patient with the same investigated risk
factors was also undertaken, with the only variables with
significant association being female gender (coefficient =
0.45; P = 0.001), pregnancy status (coefficient = 0.81; P =
0.002), and the presence of any chronic co-morbidity
(coefficient = 0.45; P = 0.049).
Severe anemia
Severe anemia was the most common clinical complica-
tion at both sites, occurring among 102 (51.8%) of the
admitted patients, with a higher proportion of females
compared to males (18.6% versus 5.0%; P < 0.001), with
more pregnant women presenting severe anemia (37.2%
versus 19.1%; P = 0.001). Surprisingly, age, chronic co-
morbidities, previous malaria history, and report of anti-
malarial use in the preceding 30 days were not associated
with severe anemia. The proportion of patients presenting
with jaundice, splenomegaly, and hepatomegaly did not
differ between patients with and without severe anemia.
No hemoglobinopathies were detected among our cohort,
reflecting the low prevalence in both study areas. Blood
transfusions were administered to 69 patients, corre-
sponding to 67.6% of individuals fulfilling the severe
anemia criteria, illustrating its effectiveness in identifying
the most severe cases. Six patients with severe anemia
experienced fatal outcomes (fatality rate = 6.0%).
Acute renal failure
Acute kidney injury was characterized in a total of 27
patients from both sites, 26 above the age of 12. A simi-
lar proportion of both genders was affected, with only
two pregnant women presenting this complication. The
mean creatinine at presentation for these patients was
4.1 mg/dL (SD = 2.8), with 41.1% presenting abnormal
renal ultrasound characterized by hyperechogenicity in
the cortex, usually associated with interstitial nephritis.
Dialysis therapy was undertaken in 11 (40.7%) of these
patients, with a total of nine patients being admitted to
the ICU and five patients with this complication dying
(fatality rate = 18.5%).
Respiratory distress
Respiratory distress in our series was observed with con-
siderably higher frequency in Manaus (Table 3). Major
changes in chest X-rays were observed for eight patients
(66.7%), mainly characterized by bi-basal interstitial
opacities. No children presented with acute respiratory
distress syndrome (ARDS), and there was no association
with gender or pregnancy status in its occurrence. There
was, however, strong evidence of association of ARDS
with having initiated antimalarials previously to admission.Six of the patients presented respiratory distress upon ad-
mission, which was characterized as acute lung injury, and
of these five had begun antimalarials within the preceding
72 hours. Two patients developed ARDS as part of a sys-
temic inflammatory response syndrome with multi-organ
dysfunction and subsequent death. One hundred nineteen
patients arrived with the previous diagnosis of P. vivax in-
fection and use of chloroquine (with or without prima-
quine) prescribed at other health services. Considering the
clinical presentation on admission, patients who used
antimalarials in the preceding 72 hours were more likely to
present with respiratory distress (OR = 10.7; 95% CI 2.1-
55.9). Four patients with ARDS died, resulting in a fatality
rate of 33.3%. Cover image of a patient presenting ARDS
post-chloroquine initiation.
Cerebral malaria
Cerebral malaria was characterized, following the WHO
guidelines, as impaired conscience or repeated convul-
sions. It was more common in India, affecting five pa-
tients, while only one was diagnosed in Brazil (Table 3).
Of the six patients with central nervous system syn-
dromes, four were male, and their ages ranged from 17
to 75 years of age. All patients had impaired conscious-
ness on admission, with one 22-year-old Indian female
patient also presenting with repeated seizures. Lumbar
puncture was performed on three patients without
significant changes in any of them. In one male patient
from Manaus, varicella-zoster virus was identified in the
cerebrospinal fluid (there were no changes in the cere-
brospinal fluid analysis). CT scans were performed for
three patients without pathological findings.
Other syndromes
Besides the aforementioned severity criteria, patients
also presented with hyperlactatemia, hypoglycemia, and
disseminated intravascular coagulation (Table 3). Fur-
thermore, clinical complications outside the WHO se-
vere criteria definitions were also characterized among
the admitted patients, such as mild hepatitis (ALT >
200 u/mL) in 20 patients, acalculous cholecystitis in 9 pa-
tients, and splenic rupture or infarction in 3 patients. From
the three cases with spleen-related complications, two were
diagnosed with spleen rupture characterized by very low
hemoglobin concentrations (4.7 mg/dL and 4.2 mg/dL)
and spleen hematoma observed at the CT scan, while the
patient with spleen infarction, as characterized by both
abdominal ultrasound and CT scan, presented with intense
upper right quadrant abdominal pain, with none of them
presenting any other severe manifestation, such as circula-
tory shock. All of them were managed conservatively and
recovered without further sequelae.
All pregnant women were submitted to obstetric ultra-
sound and appropriate testing, and were followed up to
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going study protocol. Apart from one patient presenting
subchorionic hematoma with subsequent abortion at
12 weeks of pregnancy, no other pregnancy-associated
complications were observed on admission. Among the 36
pregnant women with severe manifestations, the most
common complications were severe anemia (28), ARDS
(6), cerebral malaria (2) and acute kidney injury (2). All
four pregnant women who died presented with ARDS,
with three of them also presenting with anemia and one of
them also presenting with acute kidney injury and circula-
tory shock. Although no autopsies were performed, no
additional causes of death were suggested.
Discriminant performance
The performance of laboratorial tests (hematology,
biochemistry, and parasitemia) to discriminate severe
cases, deaths, or cases with multiple severity criteria was
assessed using ROC curves. Except for total serum biliru-
bin, which presented a reasonable discriminative perform-
ance (AUC= 0.743; 95% CI = 0.611-0.875; P < 0.001), with
values above 2.5 mg/d presenting a sensitivity of 47.0%
and a specificity of 96.3%, resulting in an overall accuracy
of 76.7% (Figure 3) no other parameters presented good
accuracy for any of the evaluated outcomes. Parasite dens-
ity among patients who had not received antimalarials
prior to admission presented a very poor accuracy to
discriminate patients with three or more severity criteria
(AUC = 0.538; 95% CI = 0.421-0.657; P > 0.05), as did
platelet counts and alanine aminotransferase (AUC =Figure 3 ROC curves depicting the discriminatory performance of perip
95% CI = 0.421-0.657; P > 0.05); and serum total bilirubin (B) (AUC = 0.74
associated three or more criteria of severity. AUC: area under the curve; g0.417 and 0.499, respectively), indicating that these param-
eters should not be used as criteria to identify patients
with P. vivax-associated complications.
Discussion
This is, to our knowledge, the first multisite study
conducted in two very distinct geographical areas, trying to
comprehensively describe severe vivax malaria cases after
an adequate diagnosis, with PCR confirmation of exclusive
P. vivax mono-infection as an important strength. Through
additional investigations, we have been able to identify a
high number of associated co-morbidities, although by not
performing a systematic investigation in all admitted cases
from both sites, there was an important limitation on esti-
mating the prevalence of their occurrence and association
with severe syndromes, an important issue to consider
[35,36]. Furthermore, although we have tried to ascertain
the presence of previous chronic co-morbidities through
medical interviews and patient record revisions, the possi-
bility of underreporting and underdiagnosis must be
considered. Indeed, one of the main concerns of the
protocol was to exclude misdiagnosis and co-infection
with P. falciparum by applying validated and standardized
molecular methods [33], as microscopy can frequently
miss out or even misdiagnose a varied proportion of cases.
Our data provide yet again a robust confirmation of the
potential of this species to cause significant morbidity and
even mortality, a fact now widely recognized by the scien-
tific community and by WHO in its recently published se-
vere malaria monograph [37]. Indeed, the associated caseheral parasitemia before the use of antimalarials (A) (AUC= 0.538;
3; 95% CI = 0.611-0.875; P < 0.001) for differentiating P. vivax-
reen line: reference.
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the Brazilian Amazon (0.9%) and Indian Rajasthan (1.5%)
is not negligible, and is comparable to CFRs previously de-
scribed in Papua New Guinea [38] and Indonesia [18], and
not too dissimilar to those for P. falciparum in Africa
[2]. These findings must be taken cautiously, as the low
incidence of P. falciparum in the study areas and the
hospital-based design can limit comparisons and esti-
mates of community CFRs. However, when compared
the overall hospitalization and fatality rates, a striking
difference could be observed between Manaus and
Bikaner, as the latter presented much higher rates, up to
20-fold higher for fatality.
Conducting multisite studies allows for an active com-
parison of the different clinical complications and asso-
ciated rates that would be expected by the very distinct
demographic, socioeconomic characteristics, health sys-
tems features, and, especially, the local malaria transmis-
sion dynamics in the different P. vivax endemic areas.
The influence of these factors could already be observed
by comparing the descriptions of clinical epidemiology
of complications associated with this infection from dif-
ferent sites, showing that in areas of higher transmission
intensities, children are the most frequently affected
population [18,19,39,40], while in areas of moderate and
low intensities, adults contribute more to the proportion
of severe cases [7,14,41]. Our study highlighted many of
these differences. For instance, when comparing patients
hospitalized at both sites, there was evidence that the
higher proportion of patients being admitted in India
was secondary to a higher frequency of first malarial in-
fections in that location, reflecting distinctive transmission
dynamics, including a differential pattern of relapse rates
that could contribute to some degree of clinical immunity
among Brazilian patients [42,43]. The spectrum of clinical
complications in both sites was broadly similar, with se-
vere anemia being by far the most frequent of the compli-
cations, as previously described in other P. vivax endemic
settings [14,17,18,44], and followed by acute renal failure,
a complication that seems to be particularly frequent in
the two countries where the study was conducted albeit
rare elsewhere [37]. The presence of three or more sever-
ity criteria was also frequent and common at both sites.
The proportion of severe malaria cases with acute lung in-
jury/respiratory distress was, however, significantly higher
among Brazilian patients. This particular difference could
be due to a number of factors, including a higher propor-
tion of Indian patients being systematically treated with
antibiotics, or differences in parasite virulence or host gen-
etics, which could not be assessed in this study and should
be considered in future studies. However, our data point
to the beginning of antimalarial treatment as a triggering
phenomenon of respiratory distress, which needs further
investigation. There were only six episodes of cerebralmalaria among our patients, with one of them presenting
co-infection with varicella-zoster virus (VZV) isolated by
PCR from the CSF, in agreement with data from other
settings showing low rates of occurrence [45].
There were 10 deaths among our admitted patients’
series, and although there was low power for assessment
of prognostic factors, there was evidence that female gen-
der (probably confounded by the risk conferred by preg-
nancy) and chronic co-morbidities were associated with a
higher risk of dying. One of the most striking findings in
this study was the confirmation that pregnancy seems to
be a clear risk factor for severe vivax malaria and even for
death (despite being only borderline significant). It has
been argued that, unlike P. falciparum, P. vivax rarely
causes severe malaria in pregnant women [37,46-48]; how-
ever, our series confirms a very high and almost identi-
cal proportion (above 2/3 in both sites) of pregnancies
among the cases of severe malaria occurring in women
of reproductive age, and four maternal deaths (all occur-
ring in Bikaner). Pregnant women were systematically eval-
uated for obstetric complications, allowing us to diagnose
an abortion occurring as a consequence of a subchorionic
hematoma which we attributed to a malaria-related compli-
cation, leading us to hypothesize that further studies aimed
at this population could properly detect and estimate the
pregnancy-related burden of P. vivax infection. We were
also able to detect the frequent occurrence of pregnancy-
related complications such as subchorionic hematoma. On
the other hand, the histopathological evidence in the litera-
ture points to minor damage of P. vivax-infected placentas
[49,50]. Ongoing studies specifically targeting malaria in
pregnancy in malaria endemic areas should help clarify the
specific contribution of this parasite in causing maternal
morbidity and death.
The occurrence of co-morbidities has been associated
with higher morbidity of malaria in different African
locations, starting with HIV infection but also including
other viral and bacterial co-infections [51-54], stressing
the importance of investigating their occurrence and
possibly promoting joint management strategies for
common concurrent conditions in many tropical areas
[55]. Bacterial systemic concurrent infections were rarely
observed in Manaus, which could be a potential reflec-
tion that among adult patients the concomitant occur-
rence of bacterial infection seems much rarer than that
among P. falciparum-infected children [56]. Yet other
studies have reported similar rates affecting both age
groups [57], in which factors associated with each setting
could be playing a higher role, a topic we could not ex-
plore due to the systematic use of antibiotics in Bikaner.
There were, however, important differences in the preva-
lence of co-morbidities in Manaus and Bikaner, with the
former presenting considerably higher frequencies of both
acute and chronic illnesses. The difference in the observed
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areas is a reflection of the local epidemiology influ-
enced by the demographic and socioeconomic struc-
tures, and also of the health systems’ capacities to
diagnose and detect concomitant illnesses. Previous
studies from the Brazilian Amazon region had already
described the joint occurrence of malaria simultan-
eously with other health conditions, either acting as a
contributing factor for severe manifestation or eventu-
ally being an incidental finding in patients with other
severe diseases leading to critical illness or even fatal
outcomes [14,25,58]. In a scenario where many tropical
regions are facing epidemiological transition, the occur-
rence of P. vivax infection in individuals with chronic
diseases is likely to become an important problem in
these areas [59-61], putting a great deal of stress on and
requiring effective recognition and management by
local health systems.
We have been able to characterize a diverse range of
clinical complications among the included patients, in-
cluding a higher risk for death among the patients devel-
oping ARDS, which was more frequent in patients who
had started antimalarials prior to hospitalization, similar
to previously described cases [12,62]. Other clinical syn-
dromes were also observed to occur with considerable
frequency, noteworthy anemia requiring transfusion and
acute renal failure, with cerebral malaria remaining a
rare and intriguing manifestation within this infection
[45]. The WHO severe malaria criteria were initially de-
veloped to identify individuals with P. falciparum infec-
tion at higher risk of death [63], and there have been
discussions among experts on the need to define specific
severity criteria to be applied for P. vivax infection. Our
study demonstrates that the application of the WHO cri-
teria can reliably identify the patients at higher risk of
complications, who therefore require more urgent and in-
tensive care, which further agrees with previous pediatric
data from the same research group [15]. A comprehensive
analysis of the array of complications observed among the
patients in our study and in the published literature pro-
vides reassurance of these findings by demonstrating that
the spectrum of clinical manifestations is broadly covered
by these definitions [12,25], with unusual manifestations
being rarely reported. However, it seems important to
highlight that severity derived from the use of primaquine
among G6PD-deficient individuals, or splenic rupture, two
well-known complications mostly seen in vivax infections
[58,64], are not included in the current WHO definitions
and should be carefully considered by clinicians working
in vivax endemic areas. Furthermore, one must consider
that in primary and community healthcare units, the
characterization of the fulfillment of all WHO criteria is
not possible due to the unavailability of laboratory facil-
ities. More easily applicable guidelines to identify severelyill patients regardless of etiology must be used by health
professionals to assist with decisions on referral or more
aggressive management.
Although it is not currently possible to reliably esti-
mate the total parasite biomass in P. vivax infection due
to the difficulty of assessing the extent of cytoadhesion
[65] and spleen sequestration [66], we were able to
observe that parasite densities within the higher quartile
were associated with higher risk of severity. Among the
clinical and laboratory markers, only total bilirubin
presented a high discriminative performance to identify
more than three criteria of severe disease, showing that
although jaundice was justifiably excluded from the
WHO severe malaria criteria, it still has an important
prognostic value and should not be dismissed by health
professionals in their initial assessment of P. vivax-
infected patients. Intense abdominal pain and low
hemoglobin levels should prompt health professionals
to consider the diagnosis of spleen rupture or infarction
and take the appropriate diagnostic and management
procedures [64].
Our study has some clear limitations that need to be
addressed. We decided to focus on providing a more
comprehensive description of the clinical manifestations
and complications associated with P. vivax infection in
detriment to comparing disease expression between sites
due to lack of adequate power and heterogeneity of proce-
dures, undermining what could have been an important
output from this study. The unrepresentativeness of
children at both sites probably reflects the fact that
neither of the sites is a reference center for pediatric
populations, albeit publications from both locations
have previously described severe manifestation among
P. vivax-infected children [15,16]. The fact that the
decisions to admit patients were made at the attending
physician’s discretion may have resulted in added selec-
tion bias, which we tried to minimize by applying the
WHO severe malaria criteria and determining the oc-
currence of more than three criteria (as a surrogate for
more severe disease). Note also that there are important
differences in the health system organization as well as
particular disparities in the management of cases, such
as for example the systematic use of antibiotics upon
admission in India. Ensuring that both sites followed the
common protocol proved also to be challenging, and in
some cases probably hinders some of the comparisons
in this study, especially regarding the presence of co-
morbidities, such as malnutrition and other co-infections.
Also, by not systematically measuring some immune mol-
ecules that have been associated with clinical complica-
tions of this infection, such as superoxide dismutase-1
[67], an opportunity was missed to properly evaluate the
prognostic value of some promising biomarkers that
could be of potential utility for future case management.
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This study has provided robust evidence asserting the
role of P. vivax as a cause of severe human disease and
death. Indeed, this infection commonly progresses with
severe manifestations, and the development of severe
symptomatology seems to be more frequent among fe-
males, pregnant women, individuals presenting with their
first malarial infection, and those with acute or chronic
co-morbidities. Although the overall the overall fatality
rates are in concordance with findings from other P. vivax
endemic areas, we observed differences between sites on
specific disease manifestations and outcomes, which still
require further and more comprehensive studies to be
conducted to better elucidate the mechanisms and factors
influencing disease expression. Only by understanding the
underlying pathophysiological mechanisms by which this
species initiates and modifies organ functions, ultimately
leading to clinical disease, as well as the role of the socio-
economic and health systems, will we be able to start
answering the many pending questions related to this
never-to-be-called-again benign parasite.
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